Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Illumina Down Over 14%, On Pace For Largest Percent Decrease Since May 2022 -- Data Talk

Illumina Down Over 14%, On Pace For Largest Percent Decrease Since May 2022 -- Data Talk

Dow JonesDow Jones2026/10/30 14:44

Illumina, Inc. (ILMN) is currently at $248.55, down $41.51 or 14.31%

--Would be lowest close since Sept. 22, 2026, when it closed at $247.46

--On pace for largest percent decrease since May 6, 2022, when it fell 14.63%

--Snaps a five day winning streak

--Down 7.75% this week; worst weekly performance since the week ending Aug. 7, 2026, when it fell 8.36%

--Down 9.18% month-to-date; on pace for worst month since March 2025, when it fell 10.59%

--Up 89.5% year-to-date; on pace for best year since 2013, when it rose 98.94%

--Down 51.27% from its all-time closing high of $510.06 on Aug. 16, 2021

--Up 101.19% from 52 weeks ago (Oct. 31, 2025), when it closed at $123.54

--Down 15.37% from its 52-week closing high of $293.69 on Oct. 5, 2026

--Up 117.19% from its 52-week closing low of $114.44 on Feb. 12, 2026

--Traded as low as $245.00; lowest intraday level since Sept. 22, 2026, when it hit $234.57

--Down 15.53% at today's intraday low; largest intraday percent decrease since Nov. 10, 2023, when it fell as much as 16.81%

--Fourth worst performer in the S&P 500 today

All data as of 10:41:45 AM ET

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

October 30, 2026 10:44 ET (14:44 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12